Key Cystic Fibrosis Drugs Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The competitive landscape of the cystic fibrosis drugs market is rapidly evolving as established key players, healthcare giants, and new entrants are investing in including novel medicines. Key players in the market are focused on developing new technologies and products that cater to the stringent regulatory norms and consumer demand. These key players are adopting several strategies, such as mergers and acquisitions, joint ventures, partnerships, and novel product launches, to enhance their product base and strengthen their market position.
Top 15 Global Manufacturers in the Cystic Fibrosis Drugs Market:
|
Company Name |
Country |
2024 Market Share (%) |
|
Vertex Pharmaceuticals |
USA |
40.2% |
|
AbbVie Inc. |
USA |
8.1% |
|
Roche (F. Hoffmann-La Roche) |
Switzerland |
6.2% |
|
Gilead Sciences |
USA |
5% |
|
Novartis AG |
Switzerland |
3.8% |
|
Chiesi Farmaceutici |
Italy |
xx% |
|
Viatris (formerly Mylan) |
USA |
xx% |
|
Nestlé HealthScience |
Switzerland |
xx% |
|
Genentech (Roche subsidiary) |
USA/Switzerland |
xx% |
|
Teva Pharmaceuticals |
Israel |
xx% |
|
AstraZeneca |
UK |
xx% |
|
Merck & Co. |
USA |
xx% |
|
Proteostasis Therapeutics |
USA |
xx% |
|
Alcresta Therapeutics |
USA |
xx% |
|
Sionna Therapeutics |
Canada/USA |
xx% |
Below are the areas covered for each company in the cystic fibrosis drugs market:
